Open Access

Association between interleukin‑36γ and tumor progression in non‑small cell lung cancer

  • Authors:
    • Lin Liu
    • Honghong He
    • Dan Xu
    • Yuehua Feng
    • Huijun Zhou
    • Liyan Shi
    • Yanzheng Gu
    • Jian Wang
    • Yibei Zhu
  • View Affiliations

  • Published online on: January 17, 2020     https://doi.org/10.3892/ol.2020.11319
  • Pages: 2457-2465
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immunotherapy is effective in improving the survival and prognosis of patients with non‑small cell lung cancer (NSCLC), and identifying effective immunomarkers is important for immunotherapy. Interleukin (IL)‑36γ is a novel immunomarker that has an important function in the antitumor immune response. The present study investigated the association between IL‑36γ and NSCLC to provide novel insight into immunotherapy for patients with NSCLC. Tissue microarrays of lung adenocarcinoma and squamous cell carcinoma were purchased for immunohistochemical analysis of IL‑36γ expression levels and clinical parameters. In addition, fresh clinical NSCLC and adjacent normal tissue samples were collected to analyze IL‑36γ mRNA expression levels using quantitative PCR. IL‑36γ protein was primarily located in the cytoplasm, with a small quantity in the nucleus, and IL‑36γ mRNA and protein expression levels in lung cancer tissues were significantly higher compared with those in adjacent normal tissues. Elevated IL‑36γ protein expression levels were significantly associated with a higher tumor grade of lung adenocarcinoma; however, IL‑36γ mRNA expression levels were inversely associated with the clinical Tumor‑Node‑Metastasis stage in patients with lung squamous cell carcinoma. In addition, patients with adenocarcinoma with high IL‑36γ protein expression levels tended to longer post‑operative survival times. These findings indicate that IL‑36γ may have potential as an immunomarker for prediction of tumor progression and survival in patients with NSCLC.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Liu, L., He, H., Xu, D., Feng, Y., Zhou, H., Shi, L. ... Zhu, Y. (2020). Association between interleukin‑36γ and tumor progression in non‑small cell lung cancer. Oncology Letters, 19, 2457-2465. https://doi.org/10.3892/ol.2020.11319
MLA
Liu, L., He, H., Xu, D., Feng, Y., Zhou, H., Shi, L., Gu, Y., Wang, J., Zhu, Y."Association between interleukin‑36γ and tumor progression in non‑small cell lung cancer". Oncology Letters 19.3 (2020): 2457-2465.
Chicago
Liu, L., He, H., Xu, D., Feng, Y., Zhou, H., Shi, L., Gu, Y., Wang, J., Zhu, Y."Association between interleukin‑36γ and tumor progression in non‑small cell lung cancer". Oncology Letters 19, no. 3 (2020): 2457-2465. https://doi.org/10.3892/ol.2020.11319